The CE analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy confirms the importance of treatment adherence in clinical practice, since ICERs varied substantially with different adherence rates [7]. This evidence concerns the gene ACE and diabetic kidney disease.